Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +47.86%
#3 Velvet Velvet +43.20%
#4 Akedo Akedo +42.96%
#5 Black Phoenix Black Phoenix +34.22%
#6 Cross Cross +21.95%
#7 DoubleZero DoubleZero +17.10%
#8 Cap Cap +16.75%
#9 Tutorial Tutorial +15.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.76%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rang in Aktien #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktienkurs
$0.11725176
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$481.50K
Veränderung (1 Tag)
-0.20%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategorie

Healthcare
Gewinn für PHAXIAM Therapeutics S.A. (PHXM)
Gewinn im Jun 2024 TTM: $-23.51M
Laut den aktuellen Finanzberichten von PHAXIAM Therapeutics S.A. betragen die aktuellen Gewinne des Unternehmens $-23.51M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-1.28M, eine Steigerung gegenüber dem Gewinn im Jahr 2021, der $-65.34M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von PHAXIAM Therapeutics S.A. von 2016 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE